Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

被引：6
|
作者：
Fiorelli, Alfonso [1 ]
Vitiello, Fabiana [2 ]
Morgillo, Floriana [3 ]
Santagata, Mario [4 ]
Spuntarelli, Chiara [4 ]
Di Domenico, Marina [5 ]
Santini, Mario [1 ]
Bianco, Andrea [6 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Thorac Surg Unity, Dept Translat Med Sci, Naples, Italy
[2] Hosp Vincenzo Monaldi, Dept Pneumol & Oncol, Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Oncol Unit, Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Maxillo & Orofacial Unit, Naples, Italy
[5] Univ Campania Luigi Vanvitelli, Gen Pathol Unit, Naples, Italy
[6] Univ Campania Luigi Vanvitelli, Pneumol Unity, Dept Translat Med Sci, Naples, Italy
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
D O I：
10.21037/tcr.2019.06.28
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S618 / S620
页数：3
相关论文
共 50 条
  • [41] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB MONOTHERAPY IN ADVANCED PD-L1 ≥50% NON-SMALL CELL LUNG CANCER (NSCLC) IN THE IRISH SETTING
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S61 - S61
  • [42] High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer
    Kim, G.
    Ahn, S.
    Hwang, J-H.
    Lee, J-C.
    Kim, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Ozguroglu, M.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Fuang, H. G.
    Kulyaba, Y.
    Zyuhal, K.
    Scheusan, R. I.
    Baramidze, A.
    Garassino, M. C.
    Li, Y.
    Jia, X.
    Kaul, M.
    Perez, J.
    Seebach, F.
    Lowy, I.
    Pouliot, J. F.
    Kim, E.
    Rietschel, P.
    Magnan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S35 - S35
  • [44] PD-L1 expression in NSCLC and biopsy size
    Kern, I.
    Kovacevic, M.
    Janzic, U.
    Cufer, T.
    VIRCHOWS ARCHIV, 2016, 469 : S127 - S127
  • [45] Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
    Melosky, B.
    Chu, Q.
    Juergens, R. A.
    Leighl, N.
    Lonescu, D.
    Tsao, M. -S.
    McLeod, D.
    Hirsh, V.
    CANCER TREATMENT REVIEWS, 2018, 65 : 65 - 77
  • [46] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [47] Prognostic value of PD-L1 expression in locally advanced NSCLC treated with chemoradiotherapy
    Gennen, K.
    Kaesmann, L.
    Eze, C.
    Dantes, M.
    Roengvoraphoj, O.
    Taugner, J.
    Neumann, J.
    Mille, E.
    Tufman, A.
    Huber, R. M.
    Orth, M.
    Reu, S.
    Niyazi, M.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S403 - S403
  • [48] High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
    Higgs, B. W.
    Robbins, P. B.
    Blake-Haskins, J. A.
    Zhu, W.
    Morehouse, C.
    Brohawn, P. Z.
    Rebelatto, M. C.
    Yao, Y.
    Jin, X.
    Shi, L.
    Ranade, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S717 - S717
  • [49] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [50] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
12345